Persistent Tumor Mutational Burden (pTMB) May Predict Response to Immune Checkpoint Inhibitors

被引：1
|
作者：
Smith, Katherine E. R. [1 ,2 ]
Markovic, Svetomir N. [1 ]
机构：
[1] Mayo Clin, Dept Oncol, Rochester, MN USA
[2] Mayo Clin, Dept Oncol, 200,1st St SW, Rochester, MN 55905 USA
来源：
CLINICAL CHEMISTRY | 2024年 / 70卷 / 01期
关键词：
CTLA-4; BLOCKADE;
D O I：
10.1093/clinchem/hvad128
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
[No abstract available]
引用
收藏
页码：25 / 26
页数：2
相关论文
共 50 条
  • [41] A novel mutational signature-based tumor genomic subtyping method predicts response to immune checkpoint inhibitors
    Takamatsu, Shiro
    Matsumura, Noriomi
    Yamanoi, Koji
    Yamaguchi, Ken
    Hamanishi, Junzo
    Mandai, Masaki
    [J]. CANCER SCIENCE, 2022, 113 : 709 - 709
  • [42] Mutational burden, tumor immune checkpoint expression, and microsatellite instability in gynecologic malignancies: Implications for immune therapy
    Winer, I.
    Jones, N. L.
    Xiu, J.
    Ellerbrock, A.
    Brown, J.
    Herzog, T.
    [J]. GYNECOLOGIC ONCOLOGY, 2018, 149 : 45 - 45
  • [43] Tumor mutational burden assessed by a targeted NGS assay to predict clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Rothschild, Sacha
    Alborelli, Ilaria
    Leonards, Katharina
    Leuenberger, Laura P.
    Prince, Spasenija Savic
    Mertz, Kirsten D.
    Poechtrager, Severin
    Zippelius, Alfred
    Laubli, Heinz Philipp
    Haegele, Jasmin
    Tolnay, Markus
    Bubendorf, Lukas
    Quagliata, Luca
    Jermann, Philip
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] Tissue tumor mutational burden (TMB) as a biomarker of efficacy with immune checkpoint inhibitors (ICI) in metastatic gastrointestinal (mGI) cancers.
    Lentz, Robert William
    Friedrich, Tyler
    Hu, Junxiao
    Leal, Alexis Diane
    Kim, Sunnie S.
    Davis, S. Lindsey
    Purcell, Tom
    Messersmith, Wells A.
    Lieu, Christopher Hanyoung
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] Prognostic Role of Tumor Mutational Burden in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
    Huang, Taobi
    Chen, Xia
    Zhang, Huiyun
    Liang, Yuan
    Li, Longquan
    Wei, Hui
    Sun, Weiming
    Wang, Yuping
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [46] Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer
    Graf, Ryon P.
    Fisher, Virginia
    Weberpals, Janick
    Gjoerup, Ole
    Tierno, Marni B.
    Huang, Richard S. P.
    Sayegh, Nicolas
    Lin, Douglas, I
    Raskina, Kira
    Schrock, Alexa B.
    Severson, Eric
    Haberberger, James F.
    Ross, Jeffrey S.
    Creeden, James
    Levy, Mia A.
    Alexander, Brian M.
    Oxnard, Geoffrey R.
    Agarwal, Neeraj
    [J]. JAMA NETWORK OPEN, 2022, 5 (03)
  • [47] INTEGRATING TUMOR MUTATIONAL BURDEN AND TRANSCRIPTOME EXPRESSION INTO PREDICTION OF IMMUNE CHECKPOINT INHIBITOR RESPONSE AND PROGNOSIS OF PATIENTS WITH COLON CANCER
    Liang, L.
    Jiang, W.
    Zheng, Y.
    Liu, T.
    Shen, X.
    Chen, Y.
    [J]. JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2022, 73 (02):
  • [48] Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors
    Berland, Lea
    Heeke, Simon
    Humbert, Olivier
    Macocco, Adam
    Long-Mira, Elodie
    Lassalle, Sandra
    Lespinet-Fabre, Virginie
    Lalvee, Salome
    Bordone, Olivier
    Cohen, Charlotte
    Leroy, Sylvie
    Hofman, Veronique
    Hofman, Paul
    Ilie, Marius
    [J]. JOURNAL OF THORACIC DISEASE, 2019, 11 : S71 - S80
  • [49] Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
    Burcher, Kimberly M.
    Lantz, Jeffrey W.
    Gavrila, Elena
    Abreu, Arianne
    Burcher, Jack T.
    Faucheux, Andrew T.
    Xie, Amy
    Jackson, Clayton
    Song, Alexander H.
    Hughes, Ryan T.
    Lycan, Thomas, Jr.
    Bunch, Paul M.
    Furdui, Cristina M.
    Topaloglu, Umit
    D'Agostino, Ralph T. B., Jr.
    Zhang, Wei
    Porosnicu, Mercedes
    [J]. CANCERS, 2021, 13 (22)
  • [50] Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis
    Osipov, Arsen
    Lim, Su Jin
    Popovic, Aleksandra
    Azad, Nilofer S.
    Laheru, Daniel A.
    Zheng, Lei
    Jaffee, Elizabeth M.
    Wang, Hao
    Yarchoan, Mark
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (18) : 4842 - 4851
12345